Mana Capital Acquisition Corp. (Nasdaq: MAAQU; MAAQ; MAAQW;
MAAQR) (the “Company” or “Mana Capital”) today announced that its
Board of Directors has approved a second extension of the period of
time available to the Company to consummate its initial business
combination by one month from September 26, 2022 to October 26,
2022 (the “Extension”), as permitted under the Company’s amended
and restated certificate of incorporation.
In connection therewith, pursuant to the merger agreement, dated
May 27, 2022, among the Company, Mana Merger Sub, Inc., Cardio
Diagnostics, Inc. (“Cardio”), and Meeshanthini (Meesha) Dogan, as
representative of the shareholders of Cardio, Cardio is expected to
deposit $216,667 into the trust account for the Company’s public
stockholders by September 26, 2022, representing $0.033 per public
share sold in the Company’s initial public offering, which will
enable the Company to effectuate the Extension. This is the second
of up to twelve one-month extensions permitted under the Company’s
governing documents.
About Mana Capital Acquisition
Corp.
Mana Capital Acquisition Corp. is a blank check company formed
for the purpose of engaging in a merger, stock exchange, asset
acquisition, stock purchase, recapitalization, reorganization or
other similar business combination with one or more businesses or
entities. Its efforts to identify a prospective target business
will not be limited to a particular industry or geographic region,
although it intends to focus its search on target businesses
operating in North America, Europe and Asia in the healthcare,
technology, green economy, and consumer products sectors.
About Cardio Diagnostics
Cardio Diagnostics is a biotechnology company that makes
cardiovascular disease prevention and early detection more
accessible, personalized, and precise. Cardio was formed to further
develop and commercialize a proprietary Artificial Intelligence
(AI)-driven Integrated Genetic-Epigenetic EngineTM for
cardiovascular disease to become one of the leading medical
technology companies for enabling improved prevention, early
detection, and assists in treatment of cardiovascular disease.
Important Information and Where to Find it
In connection with the proposed Business Combination, Mana
Capital has filed a registration statement on Form S-4 containing
proxy materials in the form of a proxy statement with the SEC. The
Form S-4 includes a proxy statement to be distributed to holders of
Mana Capital’s common stock in connection with Mana Capital’s
solicitation of proxies for the vote by Mana Capital’s stockholders
with respect to the proposed Business Combination and other matters
as described in the Form S-4, as well as the prospectus relating to
the offer of securities to be issued to Cardio’s stockholders in
connection with the proposed Business Combination. After the Form
S-4 has been declared effective, Mana Capital will mail a
definitive proxy statement, when available, to its stockholders.
Investors and security holders and other interested parties are
urged to read the Form S-4, any amendments thereto and any other
documents filed with the SEC carefully and in their entirety when
they become available because they will contain important
information about Mana Capital, Cardio and the proposed Business
Combination. Additionally, Mana Capital will file other relevant
materials with the SEC in connection with the Business Combination.
Copies may be obtained free of charge at the SEC’s web site at
www.sec.gov. Securityholders of Mana Capital are urged to read the
Form S-4 and the other relevant materials when they become
available before making any voting decision with respect to the
proposed Business Combination because they will contain important
information about the Business Combination and the parties to the
Business Combination.
Participants in the Solicitation
Mana Capital and Cardio and their respective directors and
executive officers may be considered participants in the
solicitation of proxies with respect to the proposed Business
Combination under the rules of the SEC. Security holders may obtain
more detailed information regarding the names, affiliations, and
interests of certain of Mana Capital’s executive officers and
directors in the solicitation by reading Mana Capital’s Form S-4
and other relevant materials filed with the SEC in connection with
the Business Combination when they become available. Information
about the directors and executive officers of Mana Capital is set
forth in Mana Capital’s annual report for the year ended December
31, 2021 on Form 10-K (the “Form 10-K”), which was filed with the
SEC on March 31, 2022. Information regarding the persons who may,
under the rules of the SEC, be deemed participants in the
solicitation of the stockholders in connection with the proposed
Business Combination is set forth in the Form S-4. These documents
can be obtained free of charge at www.sec.gov.
Cardio and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the
stockholders of Mana Capital in connection with the proposed
Business Combination. A list of the names of such directors and
executive officers and information regarding their interests in the
proposed Business Combination is included in the Form S-4 filed in
connection with the proposed Business Combination.
No Offer or Solicitation
This press release is not a proxy statement or solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed Business Combination and shall not
constitute an offer to sell or a solicitation of an offer to buy
the securities of Mana Capital or Cardio, nor shall there be any
sale of any such securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of such
state or jurisdiction. No offering of securities shall be made
except by means of a prospectus meeting the requirements of Section
10 of the Securities Act of 1933, as amended, or an exemption
therefrom.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. Mana Capital’s and
Cardio’s actual results may differ from their expectations,
estimates and projections and consequently, you should not rely on
these forward-looking statements as predictions of future events.
Words such as “expect,” “estimate,” “project,” “budget,”
“forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believes,” “predicts,” “potential,” “continue,” and
similar expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, Mana Capital’s and Cardio’s expectations with respect
to future performance and anticipated financial impacts of the
Business Combination, the satisfaction of the closing conditions to
the Business Combination and the timing of the completion of the
Business Combination. These forward-looking statements involve
significant risks and uncertainties that could cause the actual
results to differ materially from the expected results. Most of
these factors are outside Mana Capital’s and Cardio’s control and
are difficult to predict. All forward-looking statements are based
upon estimates, forecasts and assumptions that, while considered
reasonable by Mana Capital and its management, and Cardio and its
management, as the case may be, are inherently uncertain and many
factors may cause the actual results to differ materially from
current expectations which include, but are not limited to: the
risks and uncertainties set forth in the sections entitled “Risk
Factors” and “Cautionary Note Regarding Forward-Looking Statements”
in Mana Capital’s Form S-1 (File No. 333-260360), Annual Report on
Form 10-K for the year ended December 31, 2021, Quarterly Reports
on Form 10-Q and registration statement on Form S-4 with the SEC
(File No. 333-265308), as amended, which is subject to change and
will include a document that serves as a prospectus and proxy
statement of Mana Capital, and other documents filed by Mana
Capital from time to time with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Nothing in this press release
should be regarded as a representation by any person that the
forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward looking
statements will be achieved. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. Mana Capital does not undertake or accept any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or any change in events, conditions or circumstances
on which any such statement is based, except as otherwise required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220922005722/en/
Mana Capital Acquisition Corp. Jonathan Intrater, CEO (413)
519-3764
Mana Capital Acquisition (NASDAQ:MAAQ)
Graphique Historique de l'Action
De Oct 2024 à Déc 2024
Mana Capital Acquisition (NASDAQ:MAAQ)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
